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Markov simulation of US pregnant women and infants under 6 months of age for 1 
calendar year, from July 1 through June 30. National statistics on live births and infant 
mortality were used to generate probabilities of delivery and infant death based on 
gestational age. Each week, women entered the cohort with new pregnancies, and left 
by delivery; infants entered by delivery and left by death or reaching 6 months of age. 
Annual inﬂ uenza-attributable rates of outpatient visits and hospitalizations for preg-
nant women and infants were obtained from the literature, and adjusted to weekly 
incidences using CDC data on inﬂ uenza-positive respiratory isolates. In the base case, 
we assumed vaccination would begin in calendar week 40, be administered at routine 
prenatal visits across all gestational ages, and continue throughout the rest of the year, 
with vaccine efﬁ cacy of 73% for prevention of maternal ﬂ u and 63% for prevention 
of ﬂ u in infants under 6 months. Costs and maternal utilities were obtained from 
previously published analyses; we used published parental utilities for relevant infant 
health states. RESULTS: Base-case cost-effectiveness was $65,112/QALY gained. 
Fifty-six percent of the reduction in morbidity was attributable to prevention of disease 
in infants, and all of this beneﬁ t was accrued by vaccination within the ﬁ rst 4 weeks 
of vaccine availability. CONCLUSIONS: Vaccination of pregnant women against 
seasonal inﬂ uenza is cost-effective, with much of the beneﬁ t derived from prevention 
of infant disease. Vaccination is most efﬁ cient when the majority of pregnant women 
are vaccinated within 4 weeks of vaccine availability.
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OBJECTIVES: To evaluate the cost-effectiveness of the combination therapy with 
dutasteride and tamsulosin (D+T) as initiation treatment versus tamsulosin (T), con-
sidered the standard of care, in the treatment of moderate to severe benign prostatic 
hyperplasia (BPH) in Spain. METHODS: A semi-Markov model was developed using 
4-year and 35-year time horizons. Data were obtained from the CombAT and litera-
ture review, and the analysis was made from the National Healthcare Service perspec-
tive. Effectiveness was measured in terms of reduction of acute urinary retention 
(AUR) events and/or BPH-related surgeries and quality adjusted life-years (QALYs). 
Health care resources were deﬁ ned by an experts’ panel, and unitary costs were 
obtained from published Spanish sources and expressed in 2010 Euros. The model 
calculates costs, AURs and/or surgeries, and QALYs related to each therapy. Costs 
and effectiveness outcomes were discounted at 3.0%. One-way and probabilistic 
sensitivity analyses were conducted to test the robustness of the model. RESULTS: 
Combination therapy with D+T improves patients’ outcomes. At 4 years, D+T patients 
have a 9.9% reduction in AURs and/or surgeries over T, reaching 43.9% at 35 years. 
At 4 and 35 years, total costs related to T treatment add up to 1,373.90c and 
5,187.37c, and total costs related to D+T are 2,184.43c and 8,630.99c, respectively. 
Therefore, at 4 years, treatment with D+T presents an additional cost of 81.66c per 
AUR and/or surgery avoided and 14,023.32c per QALY gained compared to T. At 
35 years, results were 79.10c per AUR and/or surgery avoided and 8,750.15c per 
QALY gained. Sensitivity analyses showed that results are robust. CONCLUSIONS: 
Given the assumptions, combination treatment with D+T not only represents a more 
effective alternative versus T due to the reduction in AURs and/or surgeries, but also 
is a cost-effective treatment in patients with moderate to severe BPH in Spain.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost-effectiveness studies for the top 10 highest selling drugs (~$80–95B worldwide 
sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. 
For this analysis, we segmented these drugs into categories as primary care, specialty, 
small molecules, biologics, therapy areas and availability of generic alternatives. We 
analyzed the cost-effectiveness studies that were published in peer-reviewed journals. 
Search was conducted using generic names of the drugs and the phrase “cost-effec-
tiveness” in abstract of the published study. RESULTS: During 2003–2008, the 
number of published studies on “cost-effectiveness” have increased by more than 
30%. Almost half of the published studies belong to—Remicade, Plavix and Enbrel. 
There is a large variability in CERs for same drugs for different indications, in some 
cases also varying by biomarkers. Primary care drugs had lower and less variable CERs 
than specialty drugs. Variations also exist in methodology used by different groups in 
modeling cost-effectiveness, especially for time horizon and comparator. Majority of 
primary care drugs were modeled for a time horizon of 35–40 years or lifetime to 
demonstrate cost-effectiveness. Among the top 10 drugs, quetiapine and erythropoi-
etin had the highest variability across different studies, and atorvatstatin, salmetrol/
ﬂ uticasone and clopidogrel had the most consistent ICER values across studies. CON-
CLUSIONS: This analysis shows the range, variability and methods used for calcula-
tion of ICER values for these high budget impact drugs and provides lessons for 
executives and policy makers.
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OBJECTIVES: To assess the cost-effectiveness of the anterior repair of the Pelvic organ 
prolapse (POP) with Prolift® versus the colporrhaphy (COLP), under private payer 
perspective, in Brazil. METHODS: A multi-state Markov model was developed to 
assess the evolution of a patient with anterior vaginal prolapse after COLP and 
Prolift® after 2, 4, 10 and 20 years. a panel of specialist was conducted to obtain the 
local practice and to collect the complication rates. Only direct medical costs were 
considered (SIMPRO, 2010; CBHPM 5th Ed). Clinical data, transition probabilities 
and mortality rates were taken from published sources (IBGE, 2008; Jia, X 2007). 
The base-case patient could face up to three surgical repairs if prolapse relapsed. Two 
scenarios were modeled to compare the clinical and economic impact of Prolift® as 
second line treatment; mesh grant was the assumed third line treatment for both 
scenarios. Discount rate of 5% for costs and outcomes was taken following the Brazil-
ian HTA guidelines (Vianna, 2007). One-way sensitivity analysis was conducted to 
assess the robustness of the results. RESULTS: The total costs for the ﬁ rst year were 
higher for Prolift® (R$8119 versus R$4777; incremental R$3342). For the 2nd year 
the difference in the total costs reduced (R$8659 vs. R$7435; additional R$1223) 
with better outcomes for Prolift® (incremental QALYs: 0.04) with ICER ranging from 
R$19,099 (non discounted) to R$33,207 (discounted). For the next years the ICERs 
reduced, showing long term beneﬁ ts of the adoption of Prolift®. For the fourth year 
ICER ranging from R$419 to R$532, 10th year from R$578 to R$827 and for the 
20th year ranging from R$832 to R$1291, for non discounted and discounted results. 
CONCLUSIONS: Findings suggest Prolift® as a cost-effective intervention, under the 
Brazilian private payer perspective.
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OBJECTIVES: To estimate the cost-effectiveness in relation to the efﬁ cacy of PCV-13 
among elderly (both the total population and those at increased risk) aged 65 years 
and older for the The Netherlands, for various levels of efﬁ cacy assumed. METHODS: 
Our previously published cost-effectiveness model was updated to include, age-speciﬁ c 
epidemiological data and health care utilization and costs for a hypothetical cohort 
of elderly aged over 65 years of the population of the The Netherlands. This cohort 
was followed twice- once as unvaccinated and once as a vaccinated cohort- over a 
time period of 5 years. Outcome measures included costs, life-years (LYs), quality-
adjusted life-years (QALYs) and cost-effectiveness ratios (CERs). All analyses were 
performed from a societal perspective. RESULTS: Vaccination remained well below 
the c80,000 per LY except if the vaccine was only assumed to be protective against 
bacteraemic pneumonia with a relatively low effectiveness (40%) in combination with 
a high vaccine price (c65) and indirect effects of serotype replacement would largely 
offset the direct effect of vaccination. For various assumptions, introduction PCV-13 
(assuming a 60% efﬁ cacy against invasive and non invasive disease due to vaccine 
serotypes, and a cost of c50 per vaccinated person) the incremental cost-effectiveness 
ratio varies over from cost-saving to c50,676 per LY. More probable scenarios gener-
ated cost-effectiveness ratios which would be labeled as cost-effective. CONCLU-
SIONS: In the The Netherlands, vaccination with PCV-13 is likely to be considered 
cost-effective both for the total and for the high-risk population over 65 years of age 
from a societal perspective over a ﬁ ve-year time horizon. The main limitation of this 
study was the uncertainty regarding the share of pneumococcal related pneumonia.
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OBJECTIVES: To assess the cost-effectiveness of various cervical screening strategies 
in a cohort of 12-year-old US women with (V) and without (NV) a human papillo-
mavirus (HPV) 16/18 vaccine with efﬁ cacy against vaccine and non-vaccine oncogenic 
HPV types. METHODS: A lifetime Markov model simulating the progression of HPV 
infection and subsequent cervical disease (cervical intraepithelial neoplasia (CIN), 
